Pharmaceutical

Opzelura by Incyte for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE): Likelihood of Approval

Opzelura is under clinical development by Incyte and currently in Phase II for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE).

May 17, 2024 - 04:00
Opzelura is under clinical development by Incyte and currently in Phase II for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE).
Read the original article

Tags:

Previous Article

SCDARIC-33 by Regeneron Pharmaceuticals for Refractory Acute Myeloid Leukemia: L...

Next Article

Opzelura by Incyte for Graft Versus Host Disease (GVHD): Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Medicare Advantage update pushes Wall Street to reset expectations

Medicare Advantage update pushes Wall Street to reset e...

Jan 22, 2024

Opinion: I grew up in one of Africa’s largest informal settlements. Now I’m helping heal it

Opinion: I grew up in one of Africa’s largest informal ...

Nov 25, 2023

STAT+: ‘True disruption’: Mark Cuban’s company will sell brand-name diabetes medicines from J&J

STAT+: ‘True disruption’: Mark Cuban’s company will sel...

Apr 5, 2023